It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
In heart failure, various biomarkers are established for diagnosis and risk stratification; however, little is known about the relevance of serial measurements during an episode worsening heart failure (WHF). This study sought to investigate the trajectory of natriuretic peptides and multiple novel biomarkers during hospitalization for WHF and to determine the best time point to predict outcome.
Methods and results
MOLITOR (Impact of Therapy Optimisation on the Level of Biomarkers in Patients with Acute and Decompensated Chronic Heart Failure) was an eight‐centre prospective study of 164 patients hospitalized with a primary diagnosis of WHF. C‐terminal fragment of pre‐pro‐vasopressin (copeptin), N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), mid‐regional pro‐atrial natriuretic peptide (MR‐proANP), mid‐regional pro‐adrenomedullin (MR‐proADM), and C‐terminal pro‐endothelin‐1 (CT‐proET1) were measured on admission, after 24, 48, and 72 h, and every 72 h thereafter, at discharge and follow‐up visits. Their performance to predict all‐cause mortality and rehospitalization at 90 days was compared. All biomarkers decreased during recompensation (
Conclusions
This largest sample of serial measurements of multiple biomarkers in WHF found copeptin at admission with re‐measurement at 72 h to be the best predictor of 90 day mortality and rehospitalization.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; German Centre for Cardiovascular Research DZHK, Partner Site Berlin, Berlin, Germany
2 Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin, Germany
3 Emergency Department, Clinic for Cardiology, Clinical Centre of Serbia, Belgrade, Serbia
4 Marx‐Statistics, Nuremberg, Germany
5 Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Cardiology, Waikato Hospital, Hamilton, New Zealand
6 Clinic for Cardiovascular Diseases, Clinical Center Niš, Niš, Serbia
7 Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany; Division of Innovative Trials, University Medical Center Göttingen, Göttingen, Germany
8 Center for Stroke Research, Charité – Universitätsmedizin Berlin, Berlin, Germany
9 Department of Cardiology, Clinical Hospital Zvezdara, Belgrade, Serbia
10 Department of Cardiology, General Hospital Celje, Celje, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
11 Department of Cardiology, Clinical Hospital Zvezdara, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia





